This study is in progress, not accepting new patients
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
Summary
- Eligibility
- for people ages 18-55 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jeffrey Gelfand
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jeffrey Gelfand
Dr. Gelfand is an Associate Professor of Neurology at UCSF. He specializes in caring for patients with a wide range of neuroinflammatory disorders. Dr. Gelfand conducts clinical research focused on advancing new treatments for neuroimmunological diseases and restoring neurological function. Dr. Gelfand is also an award-winning medical educator. Dr. Gelfand received an A.B.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Genentech, Inc.
- ID
- NCT02688985
- Phase
- Phase 3 Multiple Sclerosis Research Study
- Study Type
- Interventional
- Participants
- About 132 people participating
- Last Updated